A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Posttraumatic Stress Disorder

Nobilis Therapeutics Inc.0 sites190 target enrollmentJune 2021

Overview

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with PTSD.

Registry

clinicaltrials.gov

Start Date

June 2021

End Date

July 2021

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Responsible Party

Sponsor

•Patients with a current diagnosis of PTSD (documented diagnosis of PTSD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition \[DSM-5\] criteria and a Clinician Administered PTSD Scale \[CAPS-5\] total severity score of \>30).
•Male and female patients between the ages of 18 and 85 years.

•History of schizophrenia, bipolar and other psychotic disorders.
•Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma or any other respiratory conditions / diseases that may affect the respiratory function.
•Currently undergoing PTSD-targeted psychotherapy.
•Currently undergoing exposure-based psychotherapy for any condition.